Grifols SA
GRFSNext catalyst
Albumin infusion (albumin)
Cirrhosis
Get an email about GRFS's next catalysts
Track Grifols (GRFS) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (Phase 3 readout).See the timeline
2 upcoming, 1 past
Albumin infusion (albumin) Phase 2 Est. Readout
Estimated primary completion for Albumin infusion (albumin) trial (NCT06812390) in Cirrhosis. Topline data typically follows completion by weeks to months.
SourceAlpha-1 Phase 3 Est. Readout (SWIFT-SC)
Estimated primary completion for Alpha-1 trial (NCT07555483) in Alpha 1 Antitrypsin Deficiency. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
Grifols, S.A. (Catalan: ) is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Catalonia, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over 30.
WebsiteFibrin Sealant (FS) Grifols
Soft Tissue Surgical Bleeding
IVIG-PEG
Primary Immunodeficiency
Albutein
Alzheimer's Disease
Xembify
Hypogammaglobulinemia
Prolastin-C
Emphysema
Fibrin Sealant Grifols
Excessive Bleeding During Surgery
Hepatitis B immune globulin
Hepatitis B
Immune Globulin Intravenous, Caprylate/Chromatography Purified
Immunologic Deficiency Syndrome
Specific intravenous anti-hepatitis B immunoglobulin
Hepatitis B, Chronic
Plasma-derived AT-III concentrate
Antithrombin III Deficiency
IGSC
Primary Immunodeficiency
IGIV-C
Myasthenia Gravis, Generalized
Ciprofloxacin dispersion for inhalation
Non Cystic Fibrosis Bronchiectasis
Alpha-1
Alpha1-Antitrypsin Deficiency
IGIV3I Grifols
Immune (Idiopathic) Thrombocytopenic Purpura
Immunoglobulin
Alzheimer's Disease
Alpha-1 MP
Alpha 1-Antitrypsin Deficiency
GAMUNEX-C
COVID-19
Albumin
Amyotrophic Lateral Sclerosis
FS Grifols
Target Bleeding Site During Peripheral Vascular Surgery
Liquid Alpha₁-PI
Alpha₁-Antitrypsin Deficiency
alpha-1 proteinase inhibitor (human)
Alpha 1-Antitrypsin Deficiency
Immune Globulin (Human), Caprylate/Chromatography Purified
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Dextrose, in Water
Immunologic Deficiency Syndrome
Standard Medical Treatment
COVID-19
Liquid Alpha1-Proteinase Inhibitor (Human)
Alpha1-Antitrypsin Deficiency
Bovine thrombin
Hemostasis
Plasmin (Human)
Acute Ischemic Stroke
Immune Globulin Intravenous (Human)
Immunologic Deficiency Syndrome
GRF312
Dry Eye Disease
Convalescent anti-SARS-CoV-2 MBT Plasma
COVID-19
Prolastin
COVID-19
Human thrombin
Hemostasis
BeneFIX
Hemophilia B
Albumin (Human), United States Pharmacopeia (USP)
Alpha 1-Antitrypsin Deficiency
Intravenous Immune Globulin
COVID-19
Human Plasma-Derived Fibrinogen Concentrate
Congenital Afibrinogenemia
Alpha1-Proteinase Inhibitor (Human)
Cystic Fibrosis
Antithrombin III
Acquired Antithrombin III Deficiency
Plasmin
Acute Peripheral Arterial Occlusion
intramuscular hepatitis B virus immune globulin
Hepatitis B, Chronic
Immune Globulin, Caprylate/Chromatography Purified
Purpura, Thrombocytopenic, Idiopathic
Anti-thrombin III
ATIII Deficiency
AT-III (Human)
Cardiac Surgery
Alpha-1 HC
Cystic Fibrosis
Immune Globulin Intravenous (IVIG)
Sickle Cell Disease
Intravenous immunoglobulin (IVIG)
Chronic Obstructive Pulmonary Disease
IVIG
Hypogammaglobulinemia
Albumin infusion (albumin)
Cirrhosis
Albumin Infusion
Cirrhosis
Gamunex
IgG Deficiency
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Fibrin Sealant (FS) Grifols | Phase 3 | Soft Tissue Surgical Bleeding | - | - |
IVIG-PEG | Phase 3 | Primary Immunodeficiency | - | - |
Albutein | Phase 3 | Alzheimer's Disease | - | - |
Xembify | Phase 3 | Hypogammaglobulinemia | - | - |
Prolastin-C | Phase 3 | Emphysema | - | - |
Fibrin Sealant Grifols | Phase 3 | Excessive Bleeding During Surgery | - | - |
Hepatitis B immune globulin | Phase 3 | Hepatitis B | - | - |
Immune Globulin Intravenous, Caprylate/Chromatography Purified | Phase 3 | Immunologic Deficiency Syndrome | - | - |
Specific intravenous anti-hepatitis B immunoglobulin | Phase 3 | Hepatitis B, Chronic | - | - |
Plasma-derived AT-III concentrate | Phase 3 | Antithrombin III Deficiency | - | - |
IGSC | Phase 3 | Primary Immunodeficiency | - | - |
IGIV-C | Phase 3 | Myasthenia Gravis, Generalized | - | - |
Ciprofloxacin dispersion for inhalation | Phase 3 | Non Cystic Fibrosis Bronchiectasis | - | - |
Alpha-1 | Phase 3 | Alpha1-Antitrypsin Deficiency | - | - |
IGIV3I Grifols | Phase 3 | Immune (Idiopathic) Thrombocytopenic Purpura | - | - |
Immunoglobulin | Phase 3 | Alzheimer's Disease | - | - |
Alpha-1 MP | Phase 3 | Alpha 1-Antitrypsin Deficiency | - | - |
GAMUNEX-C | Phase 3 | COVID-19 | - | - |
Albumin | Phase 3 | Amyotrophic Lateral Sclerosis | - | - |
FS Grifols | Phase 3 | Target Bleeding Site During Peripheral Vascular Surgery | - | - |
Liquid Alpha₁-PI | Phase 3 | Alpha₁-Antitrypsin Deficiency | - | - |
alpha-1 proteinase inhibitor (human) | Phase 3 | Alpha 1-Antitrypsin Deficiency | - | - |
Immune Globulin (Human), Caprylate/Chromatography Purified | Phase 3 | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | - | - |
Dextrose, in Water | Phase 3 | Immunologic Deficiency Syndrome | - | - |
Standard Medical Treatment | Phase 2 | COVID-19 | - | - |
Liquid Alpha1-Proteinase Inhibitor (Human) | Phase 2 | Alpha1-Antitrypsin Deficiency | - | - |
Bovine thrombin | Phase 2 | Hemostasis | - | - |
Plasmin (Human) | Phase 2 | Acute Ischemic Stroke | - | - |
Immune Globulin Intravenous (Human) | Phase 2 | Immunologic Deficiency Syndrome | - | - |
GRF312 | Phase 2 | Dry Eye Disease | - | - |
Convalescent anti-SARS-CoV-2 MBT Plasma | Phase 2 | COVID-19 | - | - |
Prolastin | Phase 2 | COVID-19 | - | - |
Human thrombin | Phase 2 | Hemostasis | - | - |
BeneFIX | Phase 2 | Hemophilia B | - | - |
Albumin (Human), United States Pharmacopeia (USP) | Phase 2 | Alpha 1-Antitrypsin Deficiency | - | - |
Intravenous Immune Globulin | Phase 2 | COVID-19 | - | - |
Human Plasma-Derived Fibrinogen Concentrate | Phase 2 | Congenital Afibrinogenemia | - | - |
Alpha1-Proteinase Inhibitor (Human) | Phase 2 | Cystic Fibrosis | - | - |
Antithrombin III | Phase 2 | Acquired Antithrombin III Deficiency | - | - |
Plasmin | Phase 2 | Acute Peripheral Arterial Occlusion | - | - |
intramuscular hepatitis B virus immune globulin | Phase 2 | Hepatitis B, Chronic | - | - |
Immune Globulin, Caprylate/Chromatography Purified | Phase 2 | Purpura, Thrombocytopenic, Idiopathic | - | - |
Anti-thrombin III | Phase 2 | ATIII Deficiency | - | - |
AT-III (Human) | Phase 2 | Cardiac Surgery | - | - |
Alpha-1 HC | Phase 2 | Cystic Fibrosis | - | - |
Immune Globulin Intravenous (IVIG) | Phase 2 | Sickle Cell Disease | - | - |
Intravenous immunoglobulin (IVIG) | Phase 2 | Chronic Obstructive Pulmonary Disease | - | - |
IVIG | Phase 2 | Hypogammaglobulinemia | - | - |
Albumin infusion (albumin) | Phase 2 | Cirrhosis | - | - |
Albumin Infusion | Phase 2 | Cirrhosis | - | - |
Gamunex | Phase 2 | IgG Deficiency | - | - |
Frequently asked questions
What is in Grifols SA's drug pipeline?→
CatalystAlert tracks 51 drug candidates in Grifols SA's (GRFS) pipeline across Phase 3, Phase 2. Its lead program is Alpha-1 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Grifols SA's next FDA catalyst?→
Grifols SA's (GRFS) next tracked catalyst is a Phase 2 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track GRFS biotech catalysts?→
Add GRFS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Grifols SA's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.